Stock listing

BX Swiss:C17 Corvus Pharmaceuticals, Inc. Aktie

Swiss listing (BX Swiss) of Corvus Pharmaceuticals, Inc. · home listing NASDAQ:CRVS

Follow Corvus Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CRVS

$9.67 USD -0.52 (-5.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRVS

Past year +13.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$9.56 – $10.03 USDNov 20, 2026
Volume
927,517 sharesNov 20, 2026
Market cap
$815.7M USDAt the close on Nov 20, 2026 · price × 84.35M shares outstanding
52-week range
$6.39 – $26.95 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$11.86M USDMedian day 950,784 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Corvus Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CRVS · Home$9.67 USD-0.52 (-5.1%)927,517$9.84$10.03$9.555$10.19Close on Nov 20, 2026
Frankfurt:C17€8.804 EUR-0.34 (-3.7%)—€8.694€8.804€8.694€9.144Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRVS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$9.67-0.52-5.1%$9.84$10.03$9.555927,517
$10.19+0.02+0.2%$10.16$10.48$9.945987,178
$10.17-0.43-4.1%$10.84$10.84$10.10925,795
$10.60-0.04-0.4%$10.78$11.05$10.43751,024
$10.64+0.02+0.2%$10.62$10.76$10.24620,420
$10.62-0.85-7.4%$11.20$11.41$10.591,021,016
$11.47+0.10+0.9%$11.32$11.76$11.25822,119
$11.37+0.02+0.2%$11.35$11.78$11.09950,784
$11.35+0.81+7.7%$10.71$11.63$10.491,271,856
$10.54+0.81+8.3%$10.65$10.96$9.641,257,477
$9.73-0.84-7.9%$10.44$10.55$9.691,145,111
$10.57+0.74+7.5%$10.29$10.59$9.7651,271,222
$9.83+0.13+1.3%$9.73$10.06$9.73776,001
$9.70-0.33-3.3%$10.10$10.21$9.60614,265
$10.03-0.20-2.0%$10.09$10.37$9.78845,085
$10.23-0.29-2.8%$10.57$10.74$10.18852,138
$10.52-0.02-0.2%$10.40$10.70$10.29911,663
$10.54+0.09+0.9%$10.49$10.80$10.311,132,702
$10.45-0.08-0.8%$10.54$10.61$10.35981,128
$10.53-0.12-1.1%$10.58$10.65$10.08933,657
$10.65+0.60+6.0%$9.92$10.68$9.851,080,556
$10.05-0.18-1.8%$10.25$10.59$10.00868,812
$10.23+0.58+6.0%$9.67$10.33$9.651,066,930
$9.65+0.13+1.4%$9.73$10.00$9.50820,335
$9.52-0.33-3.4%$9.81$10.12$9.4331,035,600
$9.85+0.47+5.0%$9.49$10.07$9.361,000,200
$9.38-0.03-0.3%$9.31$9.50$9.21976,800
$9.41-0.64-6.4%$9.99$10.03$9.321,685,600
$10.05-0.47-4.5%$10.43$10.52$10.02719,700
$10.52+0.31+3.0%$10.21$10.71$10.081,032,300
$10.21-0.20-1.9%$10.15$10.31$9.821,881,000
$10.41-0.15-1.4%$10.25$10.65$10.251,157,100
$10.56-0.18-1.7%$10.75$10.96$10.201,441,100
$10.74-0.16-1.5%$10.88$11.15$10.45823,700
$10.90-0.03-0.3%$11.11$11.11$10.641,347,800
$10.93-0.59-5.1%$11.56$11.75$10.891,306,900
$11.52-0.24-2.0%$12.00$12.03$11.50875,700
$11.76-0.11-0.9%$12.37$12.42$11.72881,900
$11.87+0.25+2.2%$11.66$12.12$11.251,210,200
$11.62-0.18-1.5%$11.92$12.04$11.421,099,600
$11.80-0.74-5.9%$12.46$12.48$11.511,141,600
$12.54-0.90-6.7%$13.30$13.45$12.25945,200
$13.44+1.02+8.2%$12.55$13.46$12.35805,300
$12.42-0.14-1.1%$12.80$12.80$12.28939,800
$12.56+0.01+0.1%$12.53$12.61$12.254,460,300
$12.55+0.32+2.6%$12.55$12.82$12.431,534,800
$12.23-0.72-5.6%$13.00$13.15$12.18952,000
$12.95-0.16-1.2%$13.07$13.17$12.451,397,100
$13.11+0.20+1.5%$12.92$13.31$12.911,088,500
$12.91-0.03-0.2%$13.13$13.50$12.771,257,600
$12.94-0.39-2.9%$13.06$13.14$12.821,094,700
$13.33-0.60-4.3%$13.76$13.91$12.951,106,800
$13.93-0.46-3.2%$14.01$14.32$13.851,032,900
$14.39-0.26-1.8%$14.34$14.74$14.34626,900
$14.65+0.45+3.2%$14.38$14.72$13.98938,400
$14.20-0.07-0.5%$14.38$14.82$13.87619,900
$14.27+0.23+1.6%$13.86$14.30$13.84460,100
$14.04-0.12-0.8%$14.09$14.16$13.71883,000
$14.16-0.56-3.8%$14.60$14.60$13.98644,500
$14.72-0.01-0.1%$14.74$15.14$14.62508,100
$14.73+0.17+1.2%$14.55$15.04$14.34692,800
$14.56+0.47+3.3%$14.30$14.83$14.30642,200
$14.09-0.37-2.6%$14.37$14.37$13.79513,500
$14.46+0.13+0.9%$14.52$14.76$14.38473,700
$14.33-1.07-6.9%$15.15$15.31$14.14783,500
Ticker
BX Swiss:C17
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BX Swiss
Currency
CHF

What changed lately

Latest news

All Corvus Pharmaceuticals, Inc. news

Corvus Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 126 in all · newest Nov 9, 2026 · oldest 2019
Calls
18 calls with a replay · 18 with a transcript · latest Nov 5, 2026
Decks
17 decks · latest Aug 6, 2026

Where Corvus Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CRVS · Home listingNASDAQUnited StatesUSD
gettex:C17gettexGermanyEUR
LS Exchange:A2AFXSLS ExchangeGermanyEUR
Lang & Schwarz:A2AFXSLang & SchwarzGermanyEUR
Tradegate:C17TradegateGermanyEUR
BOATS:CRVSBOATSUnited StatesUSD
Dusseldorf:C17DusseldorfGermanyEUR
Frankfurt:C17FrankfurtGermanyEUR
Hamburg:C17HamburgGermanyEUR
Munich:C17MunichGermanyEUR
BX Swiss:C17 · This pageBX SwissSwitzerlandCHF
Stuttgart:C17StuttgartGermanyEUR

Valuation

Price/book 3.9× against a median of 3.1×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$613.4M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.64

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Corvus Pharmaceuticals, Inc. · NASDAQ:CRVSUS$815.7MUS$613.4Mn/an/an/a3.9×n/a0.0×1.64
Aktis Oncology, Inc. · NASDAQ:AKTSUS$868.0MUS$385.9Mn/a31.2×n/a1.9×−706.8%0.0×1.21
Latigo Biotherapeutics, Inc. · NASDAQ:LTGOUS$861.9MUS$460.7Mn/an/an/a2.2×n/a0.0×n/a
Pharming Group NV · EURONEXT:PHARMUS$840.1MUS$766.3M34.4×2.0×19.8×2.9×6.3%0.4×n/a
Odyssey Therapeutics, Inc. · NASDAQ:ODTXUS$815.2MUS$512.7Mn/an/an/a2.2×n/a0.1×1.11
NATURECELL Co., Ltd. · KRX:007390US$803.4MUS$787.5Mn/a51.4×n/a17.1×−13.2%0.0×n/a
Arbutus Biopharma Corporation · NASDAQ:ABUSUS$796.4MUS$458.9M3.6×2.5×3.1×9.3×121.2%0.0×1.10
Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595US$787.5MUS$519.4Mn/a26.6×n/a3.3×n/a0.0×n/a
Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335US$778.7MUS$600.0Mn/an/an/a5.5×n/a0.0×n/a
Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWDUS$778.1MUS$702.9M5.2×1.8×n/an/a37.4%n/a1.16
Syndax Pharmaceuticals, Inc. · NASDAQ:SNDXUS$772.7MUS$695.6Mn/a2.4×n/an/a−72.4%n/a0.64
Median of the othersUS$799.9MUS$559.7M5.2×2.5×11.4×3.1×−3.5%0.0×1.11

Forecasts

5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
31.50 USD · Analysts' mean
EPS, year to Dec 2026
-0.80 · 4 analysts

Team and board

Officers

OfficerRole
Leiv LeaChief Financial Officer
Gabriel LucianoVice President Clinical Operations
Otute AkitiVice President, CMC
Suresh MahabhashyamVice President Clinical Development
William Ben JonesSenior Vice President, Pharmaceutical Development
Jeffrey ArcaraChief Business Officer
Peter ThompsonCO-FOUNDER
Richard A MillerCHAIRMAN and CO-FOUNDER

Board

DirectorRole
Richard A MillerCHAIRMAN and CO-FOUNDER
Andrew ChanBoard Member
David MooreBoard Member
Linda S. GraisBoard Member
Peter ThompsonCO-FOUNDER
Richard A. van den BroekBoard Member

Events

Calls

CallWhenStatus
Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2026 Earnings CallThu, Nov 05, 2026 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2026 Earnings CallThu, Aug 06, 2026 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2025 Earnings CallThu, Mar 12, 2026 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2025 Earnings CallTue, Nov 04, 2025 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2025 Earnings CallThu, Aug 07, 2025 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q1 2025 Earnings CallThu, May 08, 2025 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2024 Earnings CallTue, Mar 25, 2025 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2024 Earnings CallTue, Nov 12, 2024 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2024 Earnings CallTue, Aug 06, 2024 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q1 2024 Earnings CallMon, May 06, 2024 · 4:30 PM ETReplay
All 18 calls
CallWhenStatus
Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2023 Earnings CallTue, Mar 19, 2024 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2023 Earnings CallTue, Nov 07, 2023 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2023 Earnings CallTue, Aug 08, 2023 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q1 2023 Earnings CallMon, May 08, 2023 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2022 Earnings CallTue, Mar 28, 2023 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2022 Earnings CallThu, Nov 03, 2022 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2021 Earnings CallThu, Mar 10, 2022 · 4:30 PM ETReplay
Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2020 Earnings CallThu, Jul 30, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+8.3%
Q2 2026Aug 6, 2026 · After close+0.4%
Q1 2026May 7, 2026 · After close+6.6%
Q4 2025Mar 5, 2026−11.5%
Q3 2025Nov 4, 2025 · After close−1.4%
Q2 2025Aug 7, 2025 · After close+4.4%
Q1 2025May 8, 2025 · After close+32.2%
Q4 2024Mar 17, 2025 · After close−0.6%
Q3 2024Nov 12, 2024 · After close+2.1%
Q2 2024Aug 6, 2024 · After close+9.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024 · After close−12.0%
Q4 2023Mar 19, 2024 · After close−5.6%
Q3 2023Nov 7, 2023 · After close+1.3%
Q2 2023Aug 8, 2023 · After close+7.9%
Q1 2023May 8, 2023 · After close−0.4%
Q4 2022Mar 28, 2023 · After close+11.3%
Q3 2022Nov 3, 2022 · After close−3.4%
Q2 2022Aug 8, 2022 · After close−9.4%
Q1 2022May 5, 2022 · After close−4.5%
Q4 2021Mar 10, 2022 · After close−5.0%

Open Events

Decks

DeckKindSlidesDate
Q2 2026 Earnings PresentationEarnings26 slidesAug 6, 2026
Society for Investigative Dermatology 2026Conference19 slidesMay 2026
Technical Presentation (May 2026)Technical14 slidesMay 2026
Q4 2025 Earnings PresentationEarnings37 slidesMar 12, 2026
American Society of Hematology 2025 Annual MeetingConference16 slides2025
Technical Presentation (2022)Technical15 slides2022
Technical Presentation (December 2020)Technical13 slidesDec 5, 2020
Technical Presentation (2020)Technical14 slidesDec 4, 2020
Society for Immunotherapy of Cancer (SITC) 2020Conference13 slidesNovember 2020
Technical Presentation (2020)Technical17 slides2020
All 17 decks
DeckKindSlidesDate
Technical Presentation (November 2019)Technical18 slidesNovember 2019
Technical Presentation (June 2019)Technical17 slidesJune 2019
SITC 2018 (Society for Immunotherapy of Cancer Annual Meeting)Conference15 slidesNovember 2018
ASCO 2017Conference17 slidesJune 2017
AACR Annual Meeting 2017Conference21 slidesApr 4, 2017
Technical Presentation (2017)Technical15 slides2017
ESMOConference5 slides

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$201.2M raised · US$22.15 a share · Jefferies +3
Dealers: Jefferies (co-lead), Goldman Sachs & Co. LLC (co-lead), Mizuho, Ladenburg Thalmann
Use of proceeds: Working capital and general corporate purposes, including R&D for Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma trials
Jan 23, 2026
Warrant exercise of common stock warrants
Closed: US$31.3M raised · US$3.5 a share
Buyers: Richard Miller (559,073 shares purchased for $1,956,756)
Insiders: CEO Richard Miller purchased 559,073 shares for $1,956,756 through early exercise of warrants
May 8, 2025
Warrant exercise of common stock warrants
Announced: about US$12.7M
Buyers: Samlyn Capital (exercising warrants to purchase 3,633,978 shares of common stock)
Dec 18, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Mar 22, 2016.

Price
US$15.00 a share
Shares offered
4,700,000 shares of common stock
Offering size
US$70.5 million
Underwriters' option
Up to 705,000 more shares
Listing
CRVS on the Nasdaq Global Market
Underwriters
Credit Suisse, Cowen and Company, Guggenheim Securities, Cantor Fitzgerald & Co., BTIG · In the order on the cover
Shares delivered
On or about Mar 29, 2016

Steps

StepWhen
Draft sent to the SEC in confidenceNov 6, 2015
Filed publiclyJan 4, 2016
Amended twiceNewest Mar 10, 2016
Shares registered with an exchangeMar 16, 2016
Declared effective by the SECMar 22, 2016
Final prospectus, with the priceMar 24, 2016

Open IPO · From the cover of the final prospectus (424B4) filed Mar 24, 2016

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue105.0K85.0K151.0K367.0K460.0K632.0K743.0K847.0K842.0K594.0K
Gross profit-105.0K-85.0K-151.0K-367.0K-460.0K-632.0K-743.0K-847.0K-842.0K-594.0K
Research and development33.7M19.4M16.5M24.5M29.1M31.8M38.0M38.6M46.3M29.4M
Selling, general and administrative9.25M8.16M6.88M8.10M9.52M11.9M10.9M10.6M10.2M7.62M
Operating income-43.0M-27.5M-23.4M-32.6M-38.6M-43.8M-48.9M-49.2M-56.5M-37.0M
Depreciation and amortization105.0K85.0K151.0K367.0K460.0K632.0K743.0K847.0K842.0K594.0K
EBITDA-42.9M-27.5M-23.3M-32.2M-38.2M-43.1M-48.1M-48.4M-55.7M-36.4M
Interest expense2.50M1.82M1.58M654.0K15.0K540.0K2.18M2.28M0601.0K
Income before tax-13.3M-59.1M-21.7M-41.3M-43.2M-6.00M-46.7M-46.9M-55.7M-36.4M
Income tax0000000000
Net income-15.3M-62.3M-27.0M-41.3M-43.2M-6.00M-46.7M-46.9M-55.7M-36.4M
Earnings per share, basic-0.19-1.02-0.56-0.89-1.03-0.20-1.59-1.71-2.72-2.36
Earnings per share, diluted-0.53-1.02-0.56-0.89-1.03-0.20-1.59-1.71-2.72-2.36

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents4.58M8.74M12.6M13.2M63.5M16.5M5.15M39.2M45.1M5.05M
Short-term investments52.2M43.2M14.5M29.1M5.99M27.8M72.8M75.4M44.9M129.8M
Receivables37.0K75.0K26.0K588.0K539.0K86.0K329.0K337.0K132.0K365.0K
Inventory-735.0K-667.0K-492.0K-815.0K-602.0K-852.0K-1.14M
Current assets58.2M54.4M28.0M43.7M71.3M45.3M79.3M115.6M91.2M136.0M
Property, plant and equipment220.0K151.0K236.0K353.0K451.0K906.0K1.46M2.18M2.67M3.25M
Goodwill00
Total assets71.1M68.9M45.6M68.2M109.5M85.5M83.6M118.2M94.8M140.2M
Accounts payable2.49M2.58M1.52M1.98M1.56M3.47M2.45M2.00M3.45M1.90M
Current liabilities9.38M35.4M6.87M10.8M9.69M12.1M10.2M7.03M8.97M5.94M
Long-term debt00
Total debt937.0K1.12M1.37M2.60M3.65M2.31M3.19M
Total liabilities9.91M36.3M6.87M12.1M12.3M13.4M12.5M7.90M9.94M7.35M
Shareholders' equity61.2M32.6M38.7M56.1M97.2M72.1M71.1M110.3M84.8M132.8M
Shares outstanding74.7M67.9M49.0M46.6M46.6M28.4M28.0M29.3M21.0M20.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-32.8M-25.4M-23.9M-27.0M-36.7M-34.8M-37.3M-41.0M-46.2M-27.9M
Capital spending-174.0K0-34.0K-269.0K-5.00K-76.0K-25.0K-355.0K-266.0K-2.20M
Free cash flow-33.0M-25.4M-24.0M-27.3M-36.7M-34.9M-37.3M-41.3M-46.5M-30.1M
Cash from investing-7.80M-27.5M15.5M-23.3M21.6M44.8M3.25M-30.2M84.8M-42.6M
Cash from financing36.4M49.0M7.86M062.2M1.31M24.0K65.3M1.44M71.4M
Dividends paid00
Share buybacks1.29M24.0K65.3M1.44M71.4M
Change in cash-4.16M-3.88M-539.0K-50.3M47.0M11.3M-34.0M-5.91M40.1M945.0K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
8-K · Current reportJul 22, 2026Management or board changeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Meeting outcomeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 14, 2026Current reportSEC
S-8 · Registration statement for employee plansMay 7, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
8-K · Current reportApr 23, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
8-K · Current reportMar 13, 2026Material contractSEC
424B5 · ProspectusMar 13, 2026Offer documentSEC
S-3ASR · Registration statementMar 13, 2026Offer documentSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 30, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 27, 2026Big-stake noticeSEC
8-K · Current reportJan 23, 2026Current reportSEC
424B5 · ProspectusJan 23, 2026Offer documentSEC
S-3MEFJan 21, 2026Other filingsSEC
424B5 · ProspectusJan 20, 2026Offer documentSEC
8-K · Current reportJan 20, 2026Current reportSEC
8-K · Current reportJan 20, 2026Current reportSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 17, 2025Big-stake noticeSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 6, 2025Insider tradeSEC
8-K · Current reportOct 2, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
8-K · Current reportJun 4, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMay 8, 2025Offer documentSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 1, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 9, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 9, 2025Insider tradeSEC
8-K · Current reportApr 9, 2025Management or board changeSEC
10-K · Annual reportMar 25, 2025Annual reportSEC
8-K · Current reportMar 25, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
8-K · Current reportDec 18, 2024Current reportSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K · Current reportOct 23, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveAug 16, 2024Other filingsSEC
CORRESP · Letter to the SECAug 13, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 13, 2024Other filingsSEC
S-3 · Registration statementAug 6, 2024Offer documentSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedAug 1, 2024Big-stake noticeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedMay 13, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMay 9, 2024Big-stake noticeSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMay 8, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 7, 2024Offer documentSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
4 · Change in ownershipMay 7, 2024Insider tradeSEC
4 · Change in ownershipMay 7, 2024Insider tradeSEC
8-K · Current reportMay 6, 2024Material contractSEC
8-K · Current reportMay 6, 2024ResultsSEC
424B5 · ProspectusMay 3, 2024Offer documentSEC
8-K · Current reportMay 1, 2024Current reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
10-K · Annual reportMar 19, 2024Annual reportSEC
8-K · Current reportMar 19, 2024ResultsSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
8-K · Current reportJan 23, 2024Management or board changeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
8-K · Current reportNov 7, 2023ResultsSEC
10-Q · Quarterly reportNov 7, 2023Quarterly reportSEC
8-K · Current reportSep 6, 2023Current reportSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
8-K · Current reportAug 8, 2023ResultsSEC
8-K · Current reportJun 20, 2023Meeting outcomeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipMay 16, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 9, 2023Other filingsSEC
10-Q · Quarterly reportMay 8, 2023Quarterly reportSEC
8-K · Current reportMay 8, 2023ResultsSEC
CORRESP · Letter to the SECMay 4, 2023Other filingsSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
8-K · Current reportApr 24, 2023Current reportSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
8-K · Current reportApr 3, 2023Management or board changeSEC
UPLOAD · Letter from the SECMar 31, 2023Other filingsSEC
8-K · Current reportMar 29, 2023Current reportSEC
S-3 · Registration statementMar 28, 2023Offer documentSEC
S-8 · Registration statement for employee plansMar 28, 2023Offer documentSEC
10-K · Annual reportMar 28, 2023Annual reportSEC
8-K · Current reportMar 28, 2023ResultsSEC
8-K · Current reportMar 10, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 13, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 30, 2023Big-stake noticeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
4 · Change in ownershipDec 15, 2022Insider tradeSEC
4 · Change in ownershipDec 15, 2022Insider tradeSEC
8-K/A · Current report, amendedNov 3, 2022Meeting outcomeSEC
8-K · Current reportNov 3, 2022ResultsSEC
10-Q · Quarterly reportNov 3, 2022Quarterly reportSEC
8-K · Current reportOct 28, 2022Current reportSEC
4 · Change in ownershipSep 28, 2022Insider tradeSEC
4 · Change in ownershipSep 20, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
4 · Change in ownershipAug 15, 2022Insider tradeSEC
10-Q · Quarterly reportAug 8, 2022Quarterly reportSEC
8-K · Current reportAug 8, 2022ResultsSEC
4 · Change in ownershipJun 28, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
8-K · Current reportJun 17, 2022Meeting outcomeSEC
4 · Change in ownershipJun 6, 2022Insider tradeSEC

This page holds 200 of 585 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Corvus Pharmaceuticals, Inc.’s releases · as of Nov 5, 2026

Common shares
84,353,126
Fully diluted
84,353,126

Fully diluted

LineSharesAs of
Common shares84,353,126Nov 5, 2026

Share count over time

CountShares
Nov 5, 202684,353,126

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Orbimed Advisors LLC7.17M8.5%US$82.5MSep 30, 2026
BlackRock7.1M8.4%US$81.8MSep 30, 2026
Vanguard4.73M5.6%US$54.5MSep 30, 2026
State Street3.33M3.9%US$38.4MSep 30, 2026
Hood River Capital Management LLC3.31M3.9%US$38.2MSep 30, 2026
Adams Street Partners LLC3.28M3.9%US$37.7MSep 30, 2026
T. Rowe Price3.06M3.6%US$35.2MSep 30, 2026
Wellington2.85M3.4%US$32.9MSep 30, 2026
Vivo Capital, LLC2.81M3.3%US$32.3MSep 30, 2026
Perceptive Advisors LLC2.51M3.0%US$28.9MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Deep Track Capital, LP2.49M3.0%US$28.7MSep 30, 2026
Braidwell LP1.93M2.3%US$22.2MSep 30, 2026
Foresite Capital Management VI LLC1.83M2.2%US$21.1MSep 30, 2026
Geode Capital1.8M2.1%US$20.7MSep 30, 2026
Fisher Asset Management, LLC1.04M1.2%US$12MSep 30, 2026
Catalio Capital Management, LP1.02M1.2%US$11.8MSep 30, 2026
Morgan Stanley793K0.94%US$9.13MSep 30, 2026
Adage Capital Partners Gp, L.L.C.750K0.89%US$8.64MSep 30, 2026
Two Sigma709K0.84%US$8.16MSep 30, 2026
Emerald Advisers, LLC680K0.81%US$7.83MSep 30, 2026
Goldman Sachs647K0.77%US$7.45MSep 30, 2026
Schwab643K0.76%US$7.4MSep 30, 2026
DCF Advisers, LLC642K0.76%US$7.39MSep 30, 2026
Millennium606K0.72%US$6.98MSep 30, 2026
Trexquant Investment LP584K0.69%US$6.73MSep 30, 2026
Northern Trust583K0.69%US$6.72MSep 30, 2026
UBS571K0.68%US$6.58MSep 30, 2026
Emerald Mutual Fund Advisers Trust531K0.63%US$6.12MSep 30, 2026
Bank of America520K0.62%US$5.99MSep 30, 2026
Eversept Partners, LP503K0.60%US$5.79MSep 30, 2026
Nextech Invest Ltd.450K0.53%US$5.18MSep 30, 2026
Point72 Asset Management, L.P.435K0.52%US$5.01MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.423K0.50%US$4.88MSep 30, 2026
Citadel400K0.47%US$4.61MSep 30, 2026
Blue Owl Capital Holdings LP359K0.43%US$4.13MSep 30, 2026
Jump Financial, LLC352K0.42%US$4.05MSep 30, 2026
Susquehanna310K0.37%US$3.58MSep 30, 2026
Sphera Funds Management LTD.298K0.35%US$3.43MSep 30, 2026
Propel Bio Management, LLC264K0.31%US$3.04MSep 30, 2026
Polymer Capital Management (HK) LTD264K0.31%US$3.04MSep 30, 2026
Brevan Howard Capital Management LP253K0.30%US$2.91MSep 30, 2026
Spruce Street Capital LP232K0.27%US$2.67MSep 30, 2026
SEB Asset Management AB227K0.27%US$2.61MSep 30, 2026
Diadema Partners LP205K0.24%US$2.36MSep 30, 2026
Voya Investment Management LLC197K0.23%US$2.27MSep 30, 2026
BNY196K0.23%US$2.26MSep 30, 2026
Barclays188K0.22%US$2.17MSep 30, 2026
Sei Investments Co182K0.22%US$2.09MSep 30, 2026
F/m Investments LLC172K0.20%US$1.98MSep 30, 2026
D. E. Shaw & Co., Inc.157K0.19%US$1.81MSep 30, 2026

This page holds 50 of 170 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF2.93M3.5%US$43.8MJun 30, 2026
Vanguard Total Stock Market Index Fund2.37M2.8%US$35.5MJun 30, 2026
iShares Russell 2000 ETF1.75M2.1%US$26.1MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.964K1.1%US$14.4MJun 30, 2026
Vanguard Extended Market Index Fund845K1.0%US$12.6MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund802K0.95%US$12MJun 30, 2026
Fidelity Small Cap Index Fund741K0.88%US$9.82MJul 31, 2026
Hood River Small-Cap Growth Fund707K0.84%US$10.6MJun 30, 2026
iShares Russell 2000 Growth ETF626K0.74%US$9.35MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.616K0.73%US$9.21MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Biotechnology ETF446K0.53%US$6.66MJun 30, 2026
Fidelity Extended Market Index Fund381K0.45%US$4.73MMay 31, 2026
Vanguard Russell 2000 Index Fund331K0.39%US$4.11MMay 31, 2026
Vanguard Explorer Fund291K0.34%US$3.85MJul 31, 2026
iShares Micro-Cap ETF224K0.27%US$3.34MJun 30, 2026
VictoryShares US Small Mid Cap Value Momentum ETF213K0.25%US$3.19MJun 30, 2026
Emerald Growth Fund189K0.22%US$2.86MApr 30, 2026
Emerald Growth Fund189K0.22%US$2.5MJul 31, 2026
Small Cap Growth Stock Portfolio178K0.21%US$2.66MJun 30, 2026
SmallCap Growth Fund I177K0.21%US$2.34MJul 31, 2026
Vanguard Health Care Index Fund168K0.20%US$2.08MMay 31, 2026
F/m Emerald Life Sciences Innovation ETF165K0.20%US$2.05MMay 31, 2026
Schwab Small-Cap Index Fund164K0.19%US$2.18MJul 31, 2026
Vanguard U.S. Momentum Factor ETF157K0.19%US$1.95MMay 31, 2026
The Hartford Small Company Fund147K0.17%US$1.95MJul 31, 2026
iShares Genomics Immunology and Healthcare ETF137K0.16%US$1.82MJul 31, 2026
Fidelity Total Market Index Fund135K0.16%US$1.68MMay 31, 2026
Hartford Small Cap Growth Hls Fund131K0.16%US$1.95MJun 30, 2026
Master Small Cap Index Series125K0.15%US$1.87MJun 30, 2026
Fidelity Series Total Market Index Fund112K0.13%US$1.39MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio110K0.13%US$1.37MMay 29, 2026
Tema Oncology ETF108K0.13%US$1.35MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF108K0.13%US$1.62MJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares99,6170.12%US$1.32MJul 31, 2026
Hartford Small Company Hls Fund95,2500.11%US$1.42MJun 30, 2026
T.Rowe Price Small Cap Growth Portfolio90,4910.11%US$1.35MJun 30, 2026
BlackRock Advantage Small Cap Core Fund90,2260.11%US$1.12MMay 29, 2026
Nuveen Small Cap Blend Index Fund89,6950.11%US$1.19MJul 31, 2026
ALPS Medical Breakthroughs ETF86,3470.10%US$1.07MMay 31, 2026
Hood River New Opportunities Fund83,8290.10%US$1.25MJun 30, 2026
EQ/2000 Managed Volatility Portfolio72,6760.09%US$1.09MJun 30, 2026
Fidelity Small Cap Growth Index Fund63,4400.08%US$948KJun 30, 2026
EQ/Small Company Index Portfolio63,2700.08%US$945KJun 30, 2026
Nuveen Equity Index Fund62,9330.07%US$834KJul 31, 2026
The Hartford Small Cap Growth Fund60,8910.07%US$807KJul 31, 2026
Small Cap Stock Trust60,1000.07%US$898KJun 30, 2026
Vanguard Russell 2000 Growth Index Fund60,0990.07%US$746KMay 31, 2026
Transamerica T. Rowe Price Small Cap VP58,4000.07%US$872KJun 30, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund57,2110.07%US$855KJun 30, 2026
Small Company Growth Portfolio52,0160.06%US$777KJun 30, 2026

This page holds 50 of 172 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Arcara Jeffrey
Officer: Chief Business Officer
Buy503USD 10.37US$5,216Nov 13, 2026
Arcara Jeffrey
Officer: Chief Business Officer
Buy500USD 10.71US$5,354Nov 13, 2026
Arcara Jeffrey
Officer: Chief Business Officer
Buy497USD 11.12US$5,524Nov 12, 2026
Arcara Jeffrey
Officer: Chief Business Officer
Buy3,000USD 11.46US$34,381Nov 11, 2026
Moore David Scott
Director
Buy21,700USD 11.53US$250KJun 11, 2026
Miller Richard A Md
Director, Officer: President and CEO
Buy5,000USD 12.05US$60,250May 18, 2026
Miller Richard A Md
Director, Officer: President and CEO
Buy1,932USD 12.01US$23,203May 18, 2026

Big stakes

StakeStakeSharesDateFiling
Orbimed Advisors LLC10.30%8.61MJan 23, 2026Schedule 13D
Richard A. Miller7.80%6.09MDec 31, 2025Schedule 13G
BlackRock, Inc.7.50%6.33MJun 30, 2026Schedule 13G
Sirenia Capital Management LP7.50%6.83MMar 31, 2026Schedule 13G
Adams Street Partners LLC3.90%3.28MJan 23, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Richard A. van den Broek
Other companies: Pulse Biosciences, Inc (Director · Since at least Aug 6, 2020); PhaseBio Pharmaceuticals Inc (Director · Feb 27, 2019 – May 19, 2023 · Past); Celldex Therapeutics, Inc. (Director · Dec 17, 2014 – Jun 8, 2016 · Past); Pharmacyclics Inc (Director · Oct 3, 2011 – May 26, 2015 · Past)
Board Member · Since at least Apr 8, 2025
Terry P Gould
Other companies: Icosavax Inc (Director · Jul 28, 2021 – Aug 2, 2021 · Past); Aptinyx Inc (Director · Jun 20, 2018 – May 26, 2022 · Past); OncoMed Pharmaceuticals Inc (Director · Jul 17, 2013 – Jun 22, 2016 · Past)
Director · Mar 22, 2016 – Jun 13, 2024 · Past
Jason Coloma
Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026); Maze Therapeutics, Inc. (Chief Executive Officer · Since at least Jan 30, 2025)
SVP, Chief Business Officer · Jun 8, 2016 – Jun 8, 2016 · Past
Richard A. Miller
Other companies: Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2023 · Past)
CHAIRMAN and CO-FOUNDER · Since at least Mar 22, 2016
Andrew ChanBoard Member · Since at least Apr 23, 2026
David MooreBoard Member · Since at least Oct 2, 2025
Edith P MitchellDirector · Jun 15, 2021 – Dec 6, 2023 · Past
Gabriel LucianoVice President Clinical Operations · Since at least Nov 4, 2026
Jeffrey ArcaraChief Business Officer · Since at least Feb 2, 2024
Leiv LeaChief Financial Officer · Since at least Dec 6, 2023
All 15 people
PersonSeat
Linda S. GraisBoard Member · Since at least Nov 4, 2026
Otute AkitiVice President, CMC · Since at least Nov 4, 2026
Peter ThompsonCO-FOUNDER · Since at least Nov 4, 2026
Suresh MahabhashyamVice President Clinical Development · Since at least Nov 4, 2026
William Ben JonesSenior Vice President, Pharmaceutical Development · Since at least Mar 22, 2016

Open People

Log in to ask 6ix AI your own questions about Corvus Pharmaceuticals, Inc.